CTSH

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Transforming the Research Lifecycle Through Integrated Data Management, Advanced Automation, and AI-Driven Workflows TOKYO, Aug. 16, 2026 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Research Park, research sites in Japan operated by Kyowa Kirin Co., Ltd. Benchling gives scientists a single place to capture structured data, run AI models and agents and automate the workflows that move discovery and development forward.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cognizant's share price has dropped sharply as AI disruption to the traditional consulting model and tighter H-1B visa rules spook investors. The concerns may be overblown. Cognizant does not appear to be heavily skewed towards lower-value work, the latter of which likely could be offset by AI-related services. At 12x P/E, and an 8.8% FCF yield, Cognizant appears to offer an interesting valuation relative to peers, historical valuation, and fundamentals. Cautious Buy.

Explore how Cognizant's (CTSH) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

CTSH's Q2 revenues beat estimates as Financial Services surge, while higher interest costs pressure earnings and 2026 sales guidance was trimmed.

CTSH highlights its AI shift with 8,000+ AI engagements, platform growth, large deals and plans to scale AI-led services.

Cognizant remains undervalued, trading below 10x P/E despite resilient fundamentals and positive operating leverage. I reiterate a 'Buy' rating with a conservative $80/share price target, reflecting significant upside even at modest 6-8% AEPS growth. Q2'26 results reinforce the thesis: organic revenue growth, margin expansion, robust buybacks, and double-digit EPS growth guidance.